Listing & Compliance Notices

Enveric Biosciences, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“February 6, 2024, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Enveric Biosciences, Inc. (the “Company”) that based on the Staff’s review of materials submitted by the Company to Nasdaq, the Staff determined to grant the Company an extension to regain compliance with the minimum stockholders’ equity requirement of at least $2,500,000 as set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”). The deficiency with respect to the Company’s compliance with the S”

OneMedNet Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“February 7, 2024, from the Nasdaq Stock Market (“Nasdaq”) indicating that for the preceding 30 consecutive business days, the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement. Compliance may be achieved if the Company’s MVLS closes at $50,000,000 or more for a m”

RMG Acquisition Corp. III received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“June 20, 2023, RMG Acquisition Corp. III (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market (“Nasdaq”), notifying the Company that, for the previous 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of US$35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was given 180 calendar days, or until”

SeaStar Medical Holding Corp received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2024, the Company received notification from the Staff that the Company had regained compliance with the Market Value Rule. However, the Staff indicated the Company remains non-compliant with the Minimum Bid Price Rule and therefore, as previously disclosed, the Company should present its views with respect to this deficiency at its scheduled hearing in front of the Nasdaq Hearings Panel (the “Panel”) on March 12, 2024 (the “ Hearing ”). At the hearing, the Company will present its plan to regain compliance with the Minimum Bid Price Rule. Subject to the final written decision by t”

SeaStar Medical Holding Corp received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).

“February 6, 2024, the Company received notification from the Staff that the Company had regained compliance with the Market Value Rule. However, the Staff indicated the Company remains non-compliant with the Minimum Bid Price Rule and therefore, as previously disclosed, the Company should present its views with respect to this deficiency at its scheduled hearing in front of the Nasdaq Hearings Panel (the “Panel”) on March 12, 2024 (the “ Hearing ”). At the hearing, the Company will present its plan to regain compliance with the Minimum Bid Price Rule. Subject to the final written decision by t”

DZS INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 6, 2024, DZS Inc. (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Staff Determi”

Aetherium Acquisition Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“November 27, 2023, Staff provided written notice to the Company does not comply with Listing Rule 5250(c) because it did not file its Form 10-Q for the period ended September 30, 2023. In addition, Staff has determined that the Company does not comply with the minimum 400 total holders as required by Listing Rule 5450(a)(2). Pursuant to Listing Rule 5810(d)(2), the foregoing deficiencies serve as an additional and separate basis for delisting, and as such, the Company must address this concern before a Hearings Panel if it appeals Staffs determination. On December 4, 2023, the Company appealed”

Aetherium Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)).

“November 27, 2023, Staff provided written notice to the Company does not comply with Listing Rule 5250(c) because it did not file its Form 10-Q for the period ended September 30, 2023. In addition, Staff has determined that the Company does not comply with the minimum 400 total holders as required by Listing Rule 5450(a)(2). Pursuant to Listing Rule 5810(d)(2), the foregoing deficiencies serve as an additional and separate basis for delisting, and as such, the Company must address this concern before a Hearings Panel if it appeals Staffs determination. On December 4, 2023, the Company appealed”

Banzai International, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(A)).

“February 5, 2024, the Company received a letter (the “ Letter ”) from the staff at Nasdaq notifying the Company that, for the 30 consecutive business days prior to the date of the Letter, the Company’s Minimum Value of Listed Securities (“ MVLS ”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). The staff at Nasdaq also noted in the Letter that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(3)(A), which requires listed companies to have total assets and total revenue of at least $50”

Presto Automation Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(A), 5810(c)(3)(C), 5450(a)(1)).

“Presto Automation Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50 million, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”), because the MVLS of the Company was below $50 million for the 30 consecutive business days prior to the date of the Notice. Nasdaq further indicated that, as of the date of the Notice, the Company did not comply with certain requirements under the alternative”

Kaival Brands Innovations Group, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 8, 2024, the Company received written notice from Nasdaq stating that the Company has regained compliance with the Bid Price Rule and the matter is now closed. The Common Stock will continue to trade on Nasdaq, subject to the Company’s compliance with Nasdaq’s listing rules. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: February 8, 2024 Kaival Brands Innovations Group, Inc. By: /s/ Barry M. Hopkins Barry M. Hopkins Executive Chair”

Greenlane Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(b)(1)(C), 5450(a)(1)).

“August 21, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s Class A common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its Class A common stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result of the Approval, the Market Value Requirement is no longer applicable to the Company, and the Comp”

NS Wind Down Co., Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“February 5, 2024, the Company received written notice (the “ Delisting Notice ”) from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “ Securities ”) will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, concerns regarding the residual”

MedAvail Holdings, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“: MedAvail Holdings, Inc. , Case No. 24-10148. On February 2, 2024, the Company received written notice (the “Delisting Notice”) from the staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 7 Filing and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 7 Filing and associated public interest concerns raised by it, concerns regarding the residual equity interest o”

SharpLink Gaming Ltd. received a nasdaq compliance regained notice regarding stockholders equity.

“February 7, 2024, SharpLink received formal notification from Nasdaq that the Company’s previously announced deficiency under the Rule has been cured, and the Company has regained compliance with all applicable continued listing standards. Therefore, the Hearing before the Nasdaq Hearings Panel, originally scheduled for February 20, 2024, has been cancelled. SharpLink’s ordinary shares continue to be listed and traded on Nasdaq. The Company issued a press release announcing the foregoing, which press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by”

Frontier Investment Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“February 6, 2024, Frontier Investment Corp. (“ FICV ” or the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), indicating that it was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) (the “ Listing Rules ”), for failing to hold its annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end, which is required for continued listing on the Nasdaq Global Market. The Notice has no immediate effect on the listing of the Company’s securities on Nasdaq. The Notice states that the Company has 45 calen”

Senti Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 6, 2024, the Staff granted the Company’s request for a second 180-calendar day period, or until August 5, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on Ja”

Kernel Group Holdings, Inc. received a nasdaq noncompliance notice notice regarding other (rules IM-5101-2).

“aq ”) indicating that, unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “ Panel ”), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 14, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. The Company intends to timely request a hearing before the Panel to request sufficient time to complete its previou”

Motorsport Games Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“February 5, 2024, the Nasdaq Stock Market LLC (“Nasdaq”) notified Motorsport Games Inc. (the “Company”) that, based on Nasdaq’s review of the Company and the materials submitted by the Company to Nasdaq, Nasdaq’s staff has determined to grant the Company an extension to regain compliance with Nasdaq’s minimum $2,500,000 stockholders’ equity requirement set forth in Listing Rule 5550(b)(1) (the “NCM Equity Rule”), until May 15, 2024, subject to the Company’s regaining and evidencing compliance with the NCM Equity Rule by such date. The deficiency with respect to the Company’s compliance with th”

Reborn Coffee, Inc. received a nasdaq hearing update notice regarding other (rules 5550(a)(2), 5550(b), 5620(a)).

“February 2, 2024, the Company received a letter (the “Letter”) from Nasdaq notifying the Company that the Panel had granted the Company’s request to continue its listing on Nasdaq until March 29, 2024, subject to certain conditions. The Company intends to comply with the conditions set forth by the Panel, as stated in the Letter. There can be no assurance that the Panel will afford the Company more time to complete the compliance plan it articulated in the hearing, or that the Company will be able to remain in compliance with the applicable Nasdaq listing requirements on an ongoing basis. 1 SI”

Invitae Corp received a nyse delisting notice notice regarding market value (rules 802.01D).

“February 6, 2024, the New York Stock Exchange (the “NYSE”) notified Invitae Corporation (the “Company”), and publicly announced, that the NYSE has determined to (A) commence proceedings to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (B) immediately suspend trading in the Common Stock due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company expects that its Common Stock will be quoted on the OTC Pink platform or another market operated by OTC Markets Group Inc. (the “OTC”). The OTC is a si”

INVIVO THERAPEUTICS HOLDINGS CORP. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“February 2, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Voluntary Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination and, therefore, it is expected that its common stock will be delisted, which would not affect any actions it may take in bankruptcy. Nasdaq has informed the Company that trading of the C”

ADDVANTAGE TECHNOLOGIES GROUP INC received a nasdaq deficiency notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“February 2, 2024, the Company received a letter from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company and the Chapter 7 trustee that the Staff has, in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, determined that the Company’s securities will be delisted from Nasdaq based on the following factors: (i) on January 31, 2024, the Company entered the Bankruptcy Filing and the associated public interest concerns raised by such filing; (ii) concerns regarding the residual equity interest of the existing list”

Forward Industries, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 30, 2024, the Company received notification that it had failed to regain compliance with the Rule and is not eligible for a second 180-day period because of its failure to comply with the minimum stockholders’ equity initial listing requirement. Unless the Company timely requests a hearing before an independent Nasdaq Hearings Panel (the “Panel”), the Company’s securities would be subject to delisting. Accordingly, the Company will request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of”

Jaws Mustang Acquisition Corp received a nyse_american delisting notice notice regarding other.

“February 5, 2024, Jaws Mustang Acquisition Corporation (“ JWSM ”) received written notice from NYSE American LLC (“ NYSE American ”) indicating that the staff of NYSE American has determined to commence proceedings to delist JWSM’s (i) units, each consisting of one Class A ordinary share, $0.0001 par value (“ Class A Ordinary Shares ”), and one-fourth of one redeemable warrant (“ Units ”), (ii) Class A Ordinary Shares included as part of the Units and (iii) redeemable warrants included as part of the Units (each, a “ Warrant ”), each whole Warrant exercisable for one Class A Ordinary Share at”

Stardust Power Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 29, 2024, the Company received a notice from the Nasdaq stating that the Company failed to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a). This matter serves as an additional basis for delisting the Company’s securities from Nasdaq and the Panel will consider this additional matter in its decision regarding the Company’s continued listing on Nasdaq. The Company presented its views with respect to this additional deficiency to the Panel in writing on February 5, 2024. There can be no assur”

Empery Digital Inc. received a nasdaq noncompliance notice notice regarding other (rules 5605(b), 5605(c)(2)).

“t board member, and is no longer eligible to serves as a member of the Company’s audit committee, compensation committee or nominating and governance committee. As such, the Company’s current board of directors does not have a majority of independent board members as required by Nasdaq Listing Rule 5605(b), and the Company’s audit committee no longer has three board members as required by Nasdaq Listing Rule 5605(c)(2). Pursuant to Nasdaq listing rules, the Company will have until the earlier of its next annual shareholders meeting or one year from the occurrence of the event that caused the f”

Cano Health, Inc. received a nyse delisting notice notice regarding other (rules 802.01D).

“February 5, 2024, the New York Stock Exchange (the “ NYSE ”) notified (the “ Notice ”) Cano Health, Inc. (the “ Company ”) that the NYSE had determined to (a) commence proceedings to delist the Company’s Class A common stock, par value $0.01 per share (“ Common Stock ”) and (b) immediately suspend trading in the Company’s Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of title 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4, 2024. The NYSE w”

TON Strategy Co received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 18, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“NASDAQ”) indicating that it did not meet the minimum of $2,500,000 in stockholders’ equity required by NASDAQ Listing Rule 5550(b)(1) (the “Listing Rule”) for continued listing, or the alternatives of market value of listed securities or net income from continuing operations. Pursuant to the Listing Rule and the instructions from NASDAQ, on October 9, 2023 the Company submitted a plan to regain compliance with the Listing Rule and was given an extension until February 14, 2024 to evidence compliance through a pub”

INNOVATIVE SOLUTIONS & SUPPORT INC received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)).

“January 31, 2024, Nasdaq issued a letter to the Company acknowledging the non-compliance described above and confirming that, subject to the satisfaction of applicable disclosure requirements, the Company has regained compliance with Nasdaq Listing Rule 5605(c)(2). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVATIVE SOLUTIONS AND SUPPORT, INC. Date: February 2, 2024 By: /s/ Shahram Askarpour Shahram Askarpour Chief Executive Office”

VEEA INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 31, 2024, Plum Acquisition Corp. I (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to hold an annual meeting of shareholders within twelve months of the end of its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until March 16, 2024) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 calendar days from its fi”

NRX Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“February 1, 2024, Nasdaq informed the Company that it had approved the Company’s application to transfer its listing and that the Company’s securities were transferred to The Nasdaq Capital Market at the opening of business on January 19, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: February 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel”

Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2024, the Company received a notice in the form of a letter (“ Deficiency Letter ”) from the Listing Qualifications Staff of the Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Common Stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 30, 2024, to regain compliance. The Deficiency Letter states that to regain compliance, the bid price for the Common Stock must close at $1.00”

BIOTRICITY INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“January 30, 2024, the Company received a delisting determination letter (the “Letter”) from the Staff advising the Company that the Staff had determined that the Company did not regain compliance with the MVLS Requirement by the Compliance Date because the Company’s MVLS did not close at or above $35 million for a minimum of 10 consecutive business days prior to the Compliance Date. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of business on February 8, 2024”

Checkpoint Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).

“February 2, 2024, the Company received a letter from Nasdaq confirming that the Company was no longer in compliance with the Board Independence Rule. The Company’s non-compliance with the Board Independence Rule does not have an immediate effect on the listing or trading of the Company’s common stock, which continues to be listed and traded on the Nasdaq Capital Market under the symbol “CKPT.” In accordance with Rule 5605(b)(1)(A) of the Nasdaq listing standards, the Company has until the earlier of its next annual shareholders’ meeting or January 31, 2025, to regain compliance; provided, howe”

RAPID MICRO BIOSYSTEMS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“stock”) had closed below $1.00 per share for the thirty (30) consecutive business days (December 18, 2023 through February 1, 2024) and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days to regain compliance with the Bid Price Requirement, which wi”

Tvardi Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 1, 2024, Cara Therapeutics, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 30, 2024, to regain compliance with the minimum bid price requirement. To regain com”

COMSovereign Holding Corp. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“January 29, 2024, COMSovereign Holding Corp. (the “Company”) received written notice from the Nasdaq Hearing Panel (the “Panel”) notifying the Company that the Panel had determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market effective on January 31, 2024. The Company did not meet the minimum stockholders’ equity requirement of $2,500,000 as set forth in Nasdaq Listing Rule 5550(b)(1). As a result of the delisting, the Company’s common stock and warrants began trading on the OTC Pink Market on January 31, 2024. Forward-Looking Statements This Current Report”

View, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)).

“January 26, 2024, the Staff notified the Company that it had determined that the Company’s Plan did not evidence the Company’s ability to achieve compliance with the Nasdaq continued listing requirements and therefore determined to delist the Company’s securities from Nasdaq. The Notice indicated that unless the Company appeals the delisting determination, which it intends to do, trading of the Company’s common stock will be suspended at the opening of business on February 26, 2024. The Company intends to timely request a hearing before the Nasdaq Hearings Panel (the “Panel”), which request wi”

Interactive Strength, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 26, 2024, Interactive Strength Inc. (the “Company”) received a deficiency letter from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Common Stock, and the Common Stock will continue to tra”

Z Squared Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 29, 2024, Coeptis Therapeutics Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effe”

Clene Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 30, 2024, the Company received a notice from Nasdaq that, while the Company has not regained compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), it is eligible for an additional 180 calendar day period, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement (the “January Notice”). The January Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” Nasdaq’s determination to grant an add”

RYTHM, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“January 30, 2024, the Company received formal notice that the Panel had granted the Company’s request for an exception through April 15, 2024 to evidence compliance with the Listing Rule. The compliance date of April 15, 2024 represents the full extent of the Panel’s discretion to grant continued listing while the Company is non-compliant with Nasdaq Listing Rules. Accordingly, there can be no assurance that the Company will be able to regain compliance with the Nasdaq listing rules or maintain its listing on the Nasdaq Capital Market. If the Company’s common stock is delisted, it could be mor”

HOOKIPA Pharma Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, as well as the Company’s request for a second 180-calendar day period, or until July 29, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Select Market to The Nasdaq”

HeartSciences Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 30, 2024, the Company received a letter from Nasdaq advising that the Company had been granted an additional 180-day extension to July 29, 2024, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If the Company does not regain compliance within the allotted compliance period, Nasdaq staff will provide notice that the Company’s Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The Company will continue to monitor the closing bid price of it”

Liberty Resources Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“March 7, 2024, as part of rendering its decision whether to delist the Company. We intend to hold a stockholder meeting as soon as practicable and will provide public notice of such meeting.”

Movella Holdings Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“January 26, 2024, the Company received a notice (the “Notice”) from the Staff notifying the Company that it has been granted an exception to enable the Company to regain compliance with the Rule pursuant to the following terms: on or before May 13, 2024, the Company must file the Quarterly Report, as required by the Rule. In the event the Company does not satisfy the terms of the exception, the Staff will provide written notification that the Company’s securities will be delisted. The Notice has no immediate effect on the listing of the Company’s securities. There can be no assurance that the”

ARYA Sciences Acquisition Corp IV received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 29, 2024, ARYA Sciences Acquisition Corp IV (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to hold an annual meeting of shareholders within twelve months of the end of its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until March 14, 2024) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 calendar days”

Assure Holdings Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 24, 2024, the Company received a determination letter (the “Determination Letter”) from the Staff stating that it had not regained compliance with Listing Rule 5550(a)(2) and is not eligible for a second 180 day period to regain compliance. The Company may appeal the Staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on January 31, 2024. The Company plans to timely file such an appeal and request a hearing (the “Hearing”) before a Nasdaq Hearing Panel (the “Panel”). A Hearing request will stay any delis”

Greenlane Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1), 5605(c)(2)(A)).

“January 30, 2024, the Company received a notice from Nasdaq acknowledging the fact that the Company does not meet the requirements of such rules. In accordance with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) and the Nasdaq notice, to regain compliance with the Nasdaq Listing Rules, the Company has until the earlier of its next annual stockholders meeting or January 24, 2025; or if the next annual stockholders meeting is held before July 22, 2024, then the Company must evidence compliance no later than July 22, 2024. The Board intends to identify a candidate to replace Ms. Collins and to”